Search company, investor...

Predict your next investment

Abbott company logo
Corporation
HEALTHCARE
abbott.com

See what CB Insights has to offer

Investments

15

Portfolio Exits

7

Partners & Customers

10

Service Providers

2

About Abbott

Abbott (NYSE: ABT) is a global healthcare company with a portfolio of science-based offerings in diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals.

Headquarters Location

100 Abbott Park Road

Abbott Park, Illinois, 60064,

United States

+1 224 667 6100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Abbott

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Abbott in 6 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

C

Conference Exhibitors

5,302 items

D

Diabetes

1,898 items

M

Medical Devices

4,400 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

H

Health Monitoring & Diagnostics

984 items

At-home IVD test developers, at-home sample collection device developers, at-home testing service providers, and all other companies playing in the at-home testing ecosystem. Companies tagged as #AtHomeTestingEcosystem

B

Biopharma Tech

260 items

Abbott Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Abbott Rank

Research containing Abbott

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Abbott in 2 CB Insights research briefs, most recently on Apr 23, 2020.

Latest Abbott News

Global Urinalysis Market Report to 2031 - Players Include 77 Elektronika, Abbott Laboratories, Acon Laboratories and Arkray

Nov 25, 2022

The global urinalysis market will reach $5,348.8 million by 2031, growing by 6.6% annually over 2021-2031, driven by the growing geriatric population, the prevalence of age-related diseases, the growing healthcare expenditure, and the advancing diagnostic technologies. This report is based on comprehensive research of the entire global urinalysis market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: Market Structure Porter's Fiver Forces

Abbott Investments

15 Investments

Abbott has made 15 investments. Their latest investment was in Bigfoot Biomedical as part of their Series B - II on March 3, 2018.

CBI Logo

Abbott Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/28/2018

Series B - II

Bigfoot Biomedical

$18M

Yes

3

7/30/2015

Corporate Minority

Cephea Valve Technologies

Yes

1

9/30/2014

Series B

VytronUS

$31.6M

Yes

2

11/14/2007

Series D

Subscribe to see more

$99M

Subscribe to see more

0

1/19/2007

Series B

Subscribe to see more

$99M

Subscribe to see more

0

Date

3/28/2018

7/30/2015

9/30/2014

11/14/2007

1/19/2007

Round

Series B - II

Corporate Minority

Series B

Series D

Series B

Company

Bigfoot Biomedical

Cephea Valve Technologies

VytronUS

Subscribe to see more

Subscribe to see more

Amount

$18M

$31.6M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

2

0

0

Abbott Portfolio Exits

7 Portfolio Exits

Abbott has 7 portfolio exits. Their latest portfolio exit was Hydra Biosciences on December 14, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/14/2018

Asset Sale

$99M

2

10/19/2016

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

9/16/2016

Acquired - II

Subscribe to see more

$99M

Subscribe to see more

10

7/21/2011

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

10

7/10/2007

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/14/2018

10/19/2016

9/16/2016

7/21/2011

7/10/2007

Exit

Asset Sale

Divestiture

Acquired - II

Acq - P2P

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Abbott Acquisitions

26 Acquisitions

Abbott acquired 26 companies. Their latest acquisition was Walk Vascular on September 02, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/2/2021

$99M

Acquired

2

1/16/2019

Other

$99M

$14.71M

Acquired

1

10/3/2017

$99M

Acq - P2P

2

1/5/2017

Subscribe to see more

$99M

Subscribe to see more

10

2/2/2016

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/2/2021

1/16/2019

10/3/2017

1/5/2017

2/2/2016

Investment Stage

Other

Private Equity

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$14.71M

Note

Acquired

Acquired

Acq - P2P

Subscribe to see more

Subscribe to see more

Sources

2

1

2

10

10

Abbott Partners & Customers

10 Partners and customers

Abbott has 10 strategic partners and customers. Abbott recently partnered with Novo Nordisk on November 11, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

11/17/2022

Partner

Denmark

Novo Nordisk and Abbott partner to enhance diabetes support

A partnership between Novo Nordisk and Abbott means people living with diabetes can now better review their glucose patterns to help manage the condition .

1

10/26/2022

Partner

United Kingdom

AstraZeneca, Abbott team up for diabetic kidney disease treatment

Abbott Director Heo Jeong-seon and AstraZeneca Director Shim Il pose after signing a partnership agreement in Seoul , Tuesday .

1

10/26/2022

Partner

Japan

(Taylor Glascock for KHN). $38,398 for a Single Shot of a Very Old Cancer Drug

The development of Lupron Depot as an intramuscular shot that suppressed testosterone for months at a time improved patient compliance and also enabled its maker , Abbott Laboratories , and its Japanese partner , Takeda , to extend their patents on the drug into the 2000s , said Dr. Gerald Weisberg , a former Abbott Laboratories scientist who has been critical of the company 's pricing policies .

1

9/6/2022

Vendor

South Korea

Subscribe to see more

Subscribe to see more

10

8/22/2022

Partner

Spain

Subscribe to see more

Subscribe to see more

10

Date

11/17/2022

10/26/2022

10/26/2022

9/6/2022

8/22/2022

Type

Partner

Partner

Partner

Vendor

Partner

Business Partner

Country

Denmark

United Kingdom

Japan

South Korea

Spain

News Snippet

Novo Nordisk and Abbott partner to enhance diabetes support

A partnership between Novo Nordisk and Abbott means people living with diabetes can now better review their glucose patterns to help manage the condition .

AstraZeneca, Abbott team up for diabetic kidney disease treatment

Abbott Director Heo Jeong-seon and AstraZeneca Director Shim Il pose after signing a partnership agreement in Seoul , Tuesday .

(Taylor Glascock for KHN). $38,398 for a Single Shot of a Very Old Cancer Drug

The development of Lupron Depot as an intramuscular shot that suppressed testosterone for months at a time improved patient compliance and also enabled its maker , Abbott Laboratories , and its Japanese partner , Takeda , to extend their patents on the drug into the 2000s , said Dr. Gerald Weisberg , a former Abbott Laboratories scientist who has been critical of the company 's pricing policies .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Abbott Service Providers

2 Service Providers

Abbott has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

Abbott Team

55 Team Members

Abbott has 55 team members, including , .

Name

Work History

Title

Status

Murray Lappe

U.S. Department of Transportation

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Murray Lappe

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

U.S. Department of Transportation

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Abbott to Competitors

C
Cala Health

Cala Health develops wearable neuromodulation therapies to deliver individualized peripheral nerve stimulation. It was founded in 2014 and is based in San Mateo, California.

Neuros Medical Logo
Neuros Medical

Neuros Medical focuses on the development of proprietary therapies for unmet needs to patients worldwide. The company’s patented platform technology, Electrical Nerve Block, focuses on the treatment of chronic pain in a variety of applications including post-amputation pain, chronic post surgical pain, and chronic migraine.

N
Nesos

Nēsos aims to transform disease treatment by developing brain interfaces that help the brain regain control of immune function.

Aleva Neurotherapeutics Logo
Aleva Neurotherapeutics

Aleva Neurotherapeutics develops next-generation implants for Deep Brain Stimulation (DBS) therapy that are designed to be versatile, more precise, and more efficient than currently available DBS approaches, while causing fewer side effects and complications. Aleva's microDBS technology is based on thin film microscale electrodes, which are non-toxic and bio-compatible. It allows for precise, target-specific brain stimulation which reduces the side effects and potential complications as well as the costs of DBS therapy. Moreover, its features allow for expanding the existing DBS market to new indications which cannot be addressed by currently available technologies.

Lungpacer Medical Logo
Lungpacer Medical

Lungpacer Medical develops a therapeutic solution for preserving or restoring the integrity and strength of the diaphragm muscle in critically ill patients who require mechanical ventilation. The Lungpacer system is designed to activate the diaphragm using a temporary, minimally invasive, transvascular nerve stimulation approach. Through this approach, the company seeks to save many lives, improve surviving patient outcomes and greatly reduce hospital care costs. The company was founded in 2009 and is based in Vancouver, British Columbia.

S
Stimdia Medical

Stimdia Medical develops a non-invasive lung pacing device that reduces the time required to get a patient off a ventilator, resulting in significant cost savings. Stimdia Medical was formerly known as Andarta Medical. The company was founded in 2015 and is based in Minneapolis, Minnesota.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.